Evidence map›Paper›PMID 39070749›Full record

ArticleThe Lancet regional health. Europe2024

Lanreotide versus placebo for tumour reduction in patients with a

Tessel M Boertien, Madeleine L Drent, Jan Booij, Charles B L M Majoie, Marcel P M Stokkel, Jantien Hoogmoed, Alberto M Pereira, Nienke R Biermasz, Suat Simsek, Ronald Groote Veldman and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Europe, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Functional pituitary adenoma imaging.Reviews in endocrine & metabolic disorders · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Tessel M BoertienAmsterdam UMC Location University of Amsterdam, Department of Endocrinology and Metabolism, Meibergdreef 9, Amsterdam, the Netherlands.
Madeleine L DrentAmsterdam UMC Location VU University, Department of Endocrinology and Metabolism, De Boelelaan 1117, Amsterdam, the Netherlands.
Jan BooijAmsterdam UMC Location University of Amsterdam, Department of Radiology and Nuclear Medicine, Meibergdreef 9, Amsterdam, the Netherlands.
Charles B L M MajoieAmsterdam UMC Location University of Amsterdam, Department of Radiology and Nuclear Medicine, Meibergdreef 9, Amsterdam, the Netherlands.
Marcel P M StokkelNetherlands Cancer Institute, Department of Nuclear Medicine, Amsterdam, the Netherlands.
Jantien HoogmoedAmsterdam UMC Location University of Amsterdam, Department of Neurosurgery, Neurosurgical Centre Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.
Alberto M PereiraAmsterdam UMC Location University of Amsterdam, Department of Endocrinology and Metabolism, Meibergdreef 9, Amsterdam, the Netherlands.
Nienke R BiermaszLeiden University Medical Centre, Division of Endocrinology, Centre for Endocrine Tumours Leiden (CETL), Leiden, the Netherlands.
Suat SimsekAmsterdam UMC Location VU University, Department of Endocrinology and Metabolism, De Boelelaan 1117, Amsterdam, the Netherlands.
Ronald Groote VeldmanMedical Spectrum Twente, Department of Internal Medicine, Enschede, the Netherlands.
Annick J WeteringsAmsterdam UMC Location University of Amsterdam, Department of Endocrinology and Metabolism, Meibergdreef 9, Amsterdam, the Netherlands.
Juan M VinkAmsterdam UMC Location University of Amsterdam, Department of Endocrinology and Metabolism, Meibergdreef 9, Amsterdam, the Netherlands.
Michael W T TanckAmsterdam UMC Location University of Amsterdam, Department of Epidemiology and Data Science, Meibergdreef 9, Amsterdam, the Netherlands.
Eric FliersAmsterdam UMC Location University of Amsterdam, Department of Endocrinology and Metabolism, Meibergdreef 9, Amsterdam, the Netherlands.
Peter H BisschopAmsterdam UMC Location University of Amsterdam, Department of Endocrinology and Metabolism, Meibergdreef 9, Amsterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: No established medical treatment options currently exist for patients with non-functioning pituitary macroadenoma (NFPMA). Somatostatin analogues may prevent tumour growth, but randomised controlled trials are lacking. Methods: The GALANT study was an investigator-initiated, multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 3 trial with recruitment at three academic hospitals in the Netherlands. Adult patients with a suprasellar extending NFPMA, either surgery-naïve or postoperative remnant ≥10 mm, were eligible for inclusion. Important exclusion criteria were previous sellar radiotherapy and use of dopamine receptor agonists. Somatostatin receptor expression in the NFPMA was determined through Findings: Between Nov 3, 2015, and Dec 10, 2019, 49 patients were included in the study. Forty-four patients with a Interpretation: Compared with placebo, lanreotide treatment did not reduce tumour size or growth in patients with Funding: Ipsen Farmaceutica BV.

Indexed as

68Ga-DOTATATE PET imagingLanreotideNon-functioning pituitary adenomaRandomised placebo-controlled trialSomatostatin analogue

Identifiers

PMID39070749
PMCPMC11281922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.